ARID1A and neoplasm: The likely founder clone carried missense mutations in ARID1A (p.A1239T), PIK3CA (p.H1047R) and a frame-shift deletion in TP53. The tumour was classified as treatment-resistant with Ki67 rising from 0.25 to 0.417 at surgery.